drugset / Trial / NCT01630590
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Phase 2
Completed
62 enrolled
M.D. Anderson Cancer Center
Exelixis · collabHigh Impact Clinical Research Support Program · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is learn if adding cabozantinib (also known as XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will also be studied. Cabozantinib is designed to block certain proteins in your blood that cause cancer cells to grow. This may cause cancer cells to die.
Timeline
- Start
- 2014-01-08
- Primary completion
- 2021-04-06
- Completion
- 2021-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |